Edwards Lifesciences Announces Positive Results from CLASP II TR Trial for PASCAL System

Edwards Lifesciences said its PASCAL system met the six-month primary endpoint in the CLASP II TR trial, showing superiority over medical therapy alone for tricuspid repair. Trial results showed a significant reduction in tricuspid regurgitation and sustained improvements in patient health status through one year. The findings were presented at the Transcatheter Cardiovascular Therapeutics scientific symposium.